Type 2 Diabetes, Hyperuricemia
Conditions
Interventions
Case Series:N/A
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years. 2. Newly diagnosed type 2 diabetic patients(diagnosed with type 2 diabetes within 6 months). 3. Under normal sputum diet, blood uric acid was measured twice daily on two different days: fasting venous blood was collected on the first day and the second day of the clinic, the diagnostic criteria of hyperuricemia were >420 µmol/L for men and postmenopausal women and >360 µmol/L for premenopausal women. Before this clinic,Before the clinic, if the blood uric acid level meets the above criteria within 3 months, only the blood uric acid level in the first day in the outpatient clinic should be measured and the result of blood uric acid test within 3 months should be provided. 4. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Type 2 diabetes patients who are taking hypoglycemic agents in the past month. 2. Fasting blood glucose >= 13.9mmol/L or random blood glucose >= 16.7mmol/L, or acute diabetes complications such as diabetic ketoacidosis and diabetic ketoacidosis. 3. In the past 1 month, taking drugs that affect blood uric acid (Brombromarone, allopurinol, febuxostat, probenecid, sulfinpyrazone, Chinese medicine, etc.), Acute gout attack in the past month. 4. Taking thiazide diuretics in the past month. 5. Participating in other intervention studies. 6. Severe cardiovascular and cerebrovascular disease (NYHA class 3-4) does not work with the study. 7. Severe liver dysfunction (hepatic function AST, ALT more than 2.5 times the upper limit of normal). 8. Kidney disease or moderate to severe renal insufficiency (kidney function eGFR <60 ml/min/1.73 m2). 9. Pregnant women, lactating women. 10. Women of childbearing age who are unable or unwilling to contraception during the study 11. Diagnosed as a tumor (except for stable thyroid papillary cancer) or tumor chemotherapy, radiotherapy, acute uric acid nephropathy, etc.. 12. Other circumstances that researchers believe are not suitable for research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood uricemia;urine uricemia;leukocyte antigen HLA-B*5801 gene; | — |
Countries
China
Contacts
Public ContactLixin Guo
Beijing Hospital
Outcome results
None listed